Literature DB >> 9131261

Medication compliance as a feature in drug development.

H Kastrissios1, T F Blaschke.   

Abstract

Well-designed clinical trials maximize the information that can be obtained regarding the clinical pharmacology of a drug and, in turn, can streamline and enhance the drug development process. Until recently, little emphasis has been placed on integrating the role of variability in individual patterns of drug-taking into the drug development process. With the use of electronic monitoring, the temporal relationship between an individual's pattern of dosing and the prescribed regimen may be examined, and individual drug exposure may be estimated based on the actual history of dosing. As a result, accurate estimation of exposure-response relationships (or surrogate markers of response) can be obtained. Considerations in the design of clinical trials must therefore be expanded to include appropriate methods to measure compliance, sufficient frequency of monitoring to allow the time course of response to be mapped, and the use of statistically valid methods of data analysis.

Mesh:

Substances:

Year:  1997        PMID: 9131261     DOI: 10.1146/annurev.pharmtox.37.1.451

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  18 in total

Review 1.  Accounting for noncompliance in pharmacoeconomic evaluations.

Authors:  D A Hughes; A Bagust; A Haycox; T Walley
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

2.  The odds of the three nons when an aptly prescribed medicine isn't working: non-compliance, non-absorption, non-response.

Authors:  John Urquhart
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

3.  Is concordance the primrose path to health?

Authors:  Robin E Ferner
Journal:  BMJ       Date:  2003-10-11

4.  Riboflavin as an oral tracer for monitoring compliance in clinical research.

Authors:  V M Sadagopa Ramanujam; Karl E Anderson; James J Grady; Fatima Nayeem; Lee-Jane W Lu
Journal:  Open Biomark J       Date:  2011

Review 5.  Modeling and simulation of adherence: approaches and applications in therapeutics.

Authors:  Leslie A Kenna; Line Labbé; Jeffrey S Barrett; Marc Pfister
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

6.  Factor structure and validity of the Medication Adherence Questionnaire (MAQ) with cigarette smokers trying to quit.

Authors:  Benjamin A Toll; Sherry A McKee; Daniel J Martin; Peter Jatlow; Stephanie S O'Malley
Journal:  Nicotine Tob Res       Date:  2007-05       Impact factor: 4.244

7.  Comparing gain- and loss-framed messages for smoking cessation with sustained-release bupropion: a randomized controlled trial.

Authors:  Benjamin A Toll; Stephanie S O'Malley; Nicole A Katulak; Ran Wu; Joel A Dubin; Amy Latimer; Boris Meandzija; Tony P George; Peter Jatlow; Judith L Cooney; Peter Salovey
Journal:  Psychol Addict Behav       Date:  2007-12

Review 8.  Pharmacoeconomic consequences of variable patient compliance with prescribed drug regimens.

Authors:  J Urquhart
Journal:  Pharmacoeconomics       Date:  1999-03       Impact factor: 4.981

Review 9.  How the EMERGE guideline on medication adherence can improve the quality of clinical trials.

Authors:  Lina Eliasson; Sarah Clifford; Amy Mulick; Christina Jackson; Bernard Vrijens
Journal:  Br J Clin Pharmacol       Date:  2020-02-28       Impact factor: 4.335

10.  Deficiencies in the reporting of VD and t(1/2) in the FDA approved chemotherapy drug inserts.

Authors:  Malcolm J D'Souza; Ghada J Alabed
Journal:  Pharm Rev       Date:  2010-02-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.